Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) EBT Margin (2017 - 2025)

Lexaria Bioscience's EBT Margin history spans 9 years, with the latest figure at 1543.55% for Q3 2025.

  • For Q3 2025, EBT Margin rose 107082.0% year-over-year to 1543.55%; the TTM value through Nov 2025 reached 2061.43%, down 59285.0%, while the annual FY2025 figure was 1682.58%, 44651.0% down from the prior year.
  • EBT Margin for Q3 2025 was 1543.55% at Lexaria Bioscience, up from 2155.31% in the prior quarter.
  • Across five years, EBT Margin topped out at 13.92% in Q2 2022 and bottomed at 21006.37% in Q4 2023.
  • The 5-year median for EBT Margin is 1543.55% (2025), against an average of 3257.96%.
  • The largest annual shift saw EBT Margin tumbled -1927166bps in 2023 before it soared 1954342bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 14434.31% in 2021, then surged by 88bps to 1734.71% in 2022, then crashed by -1111bps to 21006.37% in 2023, then skyrocketed by 93bps to 1462.95% in 2024, then dropped by -6bps to 1543.55% in 2025.
  • Per Business Quant, the three most recent readings for LEXX's EBT Margin are 1543.55% (Q3 2025), 2155.31% (Q2 2025), and 1581.04% (Q1 2025).